Sculptra™ is approved by the US Food and Drug Administration (FDA) for restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with human immunodeficiency virus. Until now, there were no products that had been approved by the FDA to treat facial lipoatrophy. However, that is all changing with the introduction of Sculptra™ in the United States, offering an effective option to treat the effects of
lipoatrophy.
Facial fat loss, or lipoatrophy, is the loss of fat beneath the skin, which can result in sunken cheeks, indentations, and hollow eyes. Sculptra™ is a safe, synthetic, and biocompatible material that is injected below the surface of the skin in the area of fat loss. It provides a gradual and significant increase in skin thickness, improving the appearance of folds and sunken areas. No skin testing is required.
Sculptra™ (poly-L-lactic acid) has been safely used outside the United States since 1999 in over 150,000 patients under the trade name New-Fill™.